These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Association of preoperative plasma levels of vascular endothelial growth factor and soluble vascular cell adhesion molecule-1 with lymph node status and biochemical progression after radical prostatectomy. Shariat SF; Anwuri VA; Lamb DJ; Shah NV; Wheeler TM; Slawin KM J Clin Oncol; 2004 May; 22(9):1655-63. PubMed ID: 15117988 [TBL] [Abstract][Full Text] [Related]
5. Improved prediction of disease relapse after radical prostatectomy through a panel of preoperative blood-based biomarkers. Shariat SF; Karam JA; Walz J; Roehrborn CG; Montorsi F; Margulis V; Saad F; Slawin KM; Karakiewicz PI Clin Cancer Res; 2008 Jun; 14(12):3785-91. PubMed ID: 18559597 [TBL] [Abstract][Full Text] [Related]
6. Tissue expression of transforming growth factor-beta1 and its receptors: correlation with pathologic features and biochemical progression in patients undergoing radical prostatectomy. Shariat SF; Menesses-Diaz A; Kim IY; Muramoto M; Wheeler TM; Slawin KM Urology; 2004 Jun; 63(6):1191-7. PubMed ID: 15183988 [TBL] [Abstract][Full Text] [Related]
7. Association of the circulating levels of the urokinase system of plasminogen activation with the presence of prostate cancer and invasion, progression, and metastasis. Shariat SF; Roehrborn CG; McConnell JD; Park S; Alam N; Wheeler TM; Slawin KM J Clin Oncol; 2007 Feb; 25(4):349-55. PubMed ID: 17264329 [TBL] [Abstract][Full Text] [Related]
8. Preoperative plasma HER2 and epidermal growth factor receptor for staging and prognostication in patients with clinically localized prostate cancer. Shariat SF; Bensalah K; Karam JA; Roehrborn CG; Gallina A; Lotan Y; Slawin KM; Karakiewicz PI Clin Cancer Res; 2007 Sep; 13(18 Pt 1):5377-84. PubMed ID: 17875766 [TBL] [Abstract][Full Text] [Related]
9. Elevated levels of circulating interleukin-6 and transforming growth factor-beta1 in patients with metastatic prostatic carcinoma. Adler HL; McCurdy MA; Kattan MW; Timme TL; Scardino PT; Thompson TC J Urol; 1999 Jan; 161(1):182-7. PubMed ID: 10037394 [TBL] [Abstract][Full Text] [Related]
10. Plasma levels of transforming growth factor-1beta and alpha2-macroglobulin before and after radical prostatectomy: association to clinicopathological parameters. Sinnreich O; Kratzsch J; Reichenbach A; Gläser C; Huse K; Birkenmeier G Prostate; 2004 Nov; 61(3):201-8. PubMed ID: 15368477 [TBL] [Abstract][Full Text] [Related]
11. Plasminogen activation inhibitor-1 improves the predictive accuracy of prostate cancer nomograms. Shariat SF; Park S; Trinh QD; Roehrborn CG; Slawin KM; Karakiewicz PI J Urol; 2007 Oct; 178(4 Pt 1):1229-36; discussion 1236-7. PubMed ID: 17698116 [TBL] [Abstract][Full Text] [Related]
12. Predictive value of plasma hepatocyte growth factor/scatter factor levels in patients with clinically localized prostate cancer. Gupta A; Karakiewicz PI; Roehrborn CG; Lotan Y; Zlotta AR; Shariat SF Clin Cancer Res; 2008 Nov; 14(22):7385-90. PubMed ID: 19010854 [TBL] [Abstract][Full Text] [Related]
13. Pre-treatment biomarker levels improve the accuracy of post-prostatectomy nomogram for prediction of biochemical recurrence. Svatek RS; Jeldres C; Karakiewicz PI; Suardi N; Walz J; Roehrborn CG; Montorsi F; Slawin KM; Shariat SF Prostate; 2009 Jun; 69(8):886-94. PubMed ID: 19229851 [TBL] [Abstract][Full Text] [Related]
14. Plasma transforming growth factor beta1 as a biochemical marker to predict the persistence of atrial fibrillation after the surgical maze procedure. On YK; Jeon ES; Lee SY; Shin DH; Choi JO; Sung J; Kim JS; Sung K; Park P J Thorac Cardiovasc Surg; 2009 Jun; 137(6):1515-20. PubMed ID: 19464473 [TBL] [Abstract][Full Text] [Related]
15. Predictive value of the differential expression of the urokinase plasminogen activation axis in radical prostatectomy patients. Gupta A; Lotan Y; Ashfaq R; Roehrborn CG; Raj GV; Aragaki CC; Montorsi F; Shariat SF Eur Urol; 2009 May; 55(5):1124-33. PubMed ID: 18585843 [TBL] [Abstract][Full Text] [Related]
16. Prognostic value of syndecan-1 expression in patients treated with radical prostatectomy. Shariat SF; Svatek RS; Kabbani W; Walz J; Lotan Y; Karakiewicz PI; Roehrborn CG BJU Int; 2008 Jan; 101(2):232-7. PubMed ID: 17868422 [TBL] [Abstract][Full Text] [Related]
17. Nuclear factor-kappaB-mediated transforming growth factor-beta-induced expression of vimentin is an independent predictor of biochemical recurrence after radical prostatectomy. Zhang Q; Helfand BT; Jang TL; Zhu LJ; Chen L; Yang XJ; Kozlowski J; Smith N; Kundu SD; Yang G; Raji AA; Javonovic B; Pins M; Lindholm P; Guo Y; Catalona WJ; Lee C Clin Cancer Res; 2009 May; 15(10):3557-67. PubMed ID: 19447876 [TBL] [Abstract][Full Text] [Related]
18. Circulating transforming growth factor beta 1 as a predictor of liver metastasis after resection in colorectal cancer. Tsushima H; Ito N; Tamura S; Matsuda Y; Inada M; Yabuuchi I; Imai Y; Nagashima R; Misawa H; Takeda H; Matsuzawa Y; Kawata S Clin Cancer Res; 2001 May; 7(5):1258-62. PubMed ID: 11350892 [TBL] [Abstract][Full Text] [Related]
19. Association of pre- and postoperative plasma levels of transforming growth factor beta(1) and interleukin 6 and its soluble receptor with prostate cancer progression. Shariat SF; Kattan MW; Traxel E; Andrews B; Zhu K; Wheeler TM; Slawin KM Clin Cancer Res; 2004 Mar; 10(6):1992-9. PubMed ID: 15041717 [TBL] [Abstract][Full Text] [Related]
20. A model that predicts the probability of positive imaging in prostate cancer cases with biochemical failure after initial definitive local therapy. Choueiri TK; Dreicer R; Paciorek A; Carroll PR; Konety B J Urol; 2008 Mar; 179(3):906-10; discussion 910. PubMed ID: 18207194 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]